VCEL · Vericel Corp
← all insidersBiological Products, (No Diagnostic Substances) · Listed on Nasdaq
Open-market insider flow over 30d · 90d · 180d · 365d · filter in table · CSV · JSON
Open-market trades13
Distinct insiders6
Bought$0
Sold$3.49M
Net flow$-3.49M
Recent filings
How to read this
- Filed
- Date the Form 4 was filed with the SEC. Insiders must file within 2 business days of the trade.
- Ticker
- The issuer's stock symbol. Select it to open that company's insider-activity page.
- Issuer
- The company whose shares were traded.
- Sector
- The issuer's industry (SEC SIC classification). Select a value to filter to that sector.
- Insider
- The reporting person: an officer, director, or 10% owner. Select a name to see all of their trades.
- Role
- The insider's relationship to the company: director, officer, or 10% owner.
- Code
- SEC transaction code describing the kind of transaction. Full official definitions are under “Transaction codes” below. A dot marks an open-market trade (P/S), the highest-conviction signal.
- Side
- Direction of the trade, from the filing's Acquired (A) ▲ / Disposed of (D) ▼ field: a buy or a sell.
- 10b5-1
- Trade made under a pre-arranged Rule 10b5-1 plan: scheduled in advance, not a discretionary decision (generally lower signal).
- Shares
- Number of shares in this transaction.
- Price
- Reported price per share. Blank for grants, gifts, and other trades with no stated price.
- Value
- Transaction value = shares × price. Left blank for grants, option exercises, gifts, and conversions, which have no cash price (see Own Δ for their impact).
- Owned after
- Form 4 column “Amount of Securities Beneficially Owned Following Reported Transaction(s)”: shares the insider held (directly or indirectly) immediately after this trade.
- Own Δ
- How much this trade changed the insider's own holding versus what they held just before it (not a share of the company). +45% grew it by 45%, 2.0× more than doubled it, −100% sold the entire stake, “new” built a position from nothing.
- Co. Δ
- Change in the insider's stake as a share of the whole company from this trade (transaction shares ÷ shares outstanding). The “(now …)” figure is their resulting total stake. Based on the latest reported shares outstanding; blank when unavailable.
- D/I
- Form 4 column “Ownership Form: Direct (D) or Indirect (I)”. Indirect holdings (for example, through a trust, fund, or family member) are detailed in the filing's “Nature of Indirect Beneficial Ownership.”
- Lag
- Days from the trade date to the filing date (Form 4 is due within 2 business days).
Transaction codes
Verbatim from the SEC's General Instructions for Forms 3, 4 and 5.
- P
- Open market or private purchase of non-derivative or derivative security
- S
- Open market or private sale of non-derivative or derivative security
- A
- Grant, award or other acquisition pursuant to Rule 16b-3(d)
- D
- Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
- F
- Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
- M
- Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
- G
- Bona fide gift
- C
- Conversion of derivative security
- X
- Exercise of in-the-money or at-the-money derivative security
- J
- Other acquisition or disposition (describe transaction)
| Filed ↓Date the Form 4 was filed with the SEC (due within 2 business days of the trade). | Insider | Role | CodeSEC transaction code describing the kind of transaction. See “How to read this” above for the official SEC definition of each code. The dot marks an open-market trade (P/S). | SideDirection of the trade: a buy (acquired ▲) or a sell (disposed ▼). | Shares | PriceReported price per share. Blank for trades with no stated price. | ValueTransaction value = shares × price. Left blank for grants, option exercises, gifts, and conversions, which have no cash price (see Own Δ). | Owned afterShares the insider held (directly or indirectly) immediately after this trade. | Own ΔHow much this trade changed the insider's own holding versus what they held just before it (not a share of the company). +45% grew it by 45%, 2.0× more than doubled it, −100% sold the entire stake, “new” built a position from nothing. | Co. ΔChange in the insider's stake as a share of the whole company from this trade (transaction shares ÷ shares outstanding). The “(now …)” figure is their resulting total stake in the company. Based on the latest reported shares outstanding; blank when unavailable. | Link to SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-14 | MCLAUGHLIN KEVIN F | Director | M | ▲ buy10b5-1 | 7,000→ 7,000 Common Stock | — | — | 7,000 | — | — | filing |
| 2026-08-14 | MCLAUGHLIN KEVIN F | Director | S | ▼ sell10b5-1 | 7,0000 | $44.53 | $311.7K | 18,300 | −28% | −0.01% (now 0.04%) | filing |
| 2026-08-14 | MCLAUGHLIN KEVIN F | Director | M | ▲ buy10b5-1 | 7,0000 | $13.05 | $91.3K | 25,300 | +38% | +0.01% (now 0.05%) | filing |
| 2026-08-05 | Halpin Michael | Officer (Chief Operating Officer) | M | ▲ buy10b5-1 | 10,000→ 10,000 Common Stock | — | — | 26,250 | — | — | filing |
| 2026-08-05 | Halpin Michael | Officer (Chief Operating Officer) | S | ▼ sell10b5-1 | 10,0000 | $46.84 | $468.4K | 16,394 | −38% | −0.02% (now 0.03%) | filing |
| 2026-08-05 | Halpin Michael | Officer (Chief Operating Officer) | M | ▲ buy10b5-1 | 10,0000 | $16.66 | $166.6K | 26,394 | +61% | +0.02% (now 0.05%) | filing |
| 2026-07-31 | SIEGAL JONATHAN | Officer (Principal Accounting Officer) | M | ▲ buy10b5-1 | 500→ 500 Common Stock | — | — | 3,500 | — | — | filing |
| 2026-07-31 | SIEGAL JONATHAN | Officer (Principal Accounting Officer) | M | ▲ buy10b5-1 | 2,500→ 2,500 Common Stock | — | — | 4,000 | — | — | filing |
| 2026-07-31 | SIEGAL JONATHAN | Officer (Principal Accounting Officer) | M | ▲ buy10b5-1 | 1,500→ 1,500 Common Stock | — | — | 2,698 | — | — | filing |
| 2026-07-31 | SIEGAL JONATHAN | Officer (Principal Accounting Officer) | S | ▼ sell10b5-1 | 5000 | $48.90 | $24.4K | 1,078 | −32% | −<0.01% (now <0.01%) | filing |
| 2026-07-31 | SIEGAL JONATHAN | Officer (Principal Accounting Officer) | M | ▲ buy10b5-1 | 5000 | $29.82 | $14.9K | 1,578 | +46% | +<0.01% (now <0.01%) | filing |
| 2026-07-31 | SIEGAL JONATHAN | Officer (Principal Accounting Officer) | S | ▼ sell10b5-1 | 2,5000 | $48.90 | $122.3K | 1,078 | −70% | −<0.01% (now <0.01%) | filing |
| 2026-07-31 | SIEGAL JONATHAN | Officer (Principal Accounting Officer) | M | ▲ buy10b5-1 | 2,5000 | $29.82 | $74.5K | 3,578 | 3.3× | +<0.01% (now <0.01%) | filing |
| 2026-07-31 | SIEGAL JONATHAN | Officer (Principal Accounting Officer) | S | ▼ sell10b5-1 | 1,5000 | $48.90 | $73.3K | 1,078 | −58% | −<0.01% (now <0.01%) | filing |
| 2026-07-31 | SIEGAL JONATHAN | Officer (Principal Accounting Officer) | M | ▲ buy10b5-1 | 1,5000 | $34.90 | $52.4K | 2,578 | 2.4× | +<0.01% (now <0.01%) | filing |
| 2026-06-30 | SIEGAL JONATHAN | Officer (Principal Accounting Officer) | M | ▲ buy10b5-1 | 2,500→ 2,500 Common Stock | — | — | 6,500 | — | — | filing |
| 2026-06-30 | SIEGAL JONATHAN | Officer (Principal Accounting Officer) | S | ▼ sell10b5-1 | 2,5000 | $44.90 | $112.3K | 886 | −74% | −<0.01% (now <0.01%) | filing |
| 2026-06-30 | SIEGAL JONATHAN | Officer (Principal Accounting Officer) | M | ▲ buy10b5-1 | 2,5000 | $29.82 | $74.5K | 3,386 | 3.8× | +<0.01% (now <0.01%) | filing |
| 2026-06-30 | SIEGAL JONATHAN | Officer (Principal Accounting Officer) | S | ▼ sell10b5-1 | 2320 | $44.90 | $10.4K | 886 | −21% | −<0.01% (now <0.01%) | filing |
| 2026-06-30 | Mara Joseph Anthony Jr | Officer (Chief Financial Officer) | S | ▼ sell10b5-1 | 5,0000 | $44.75 | $223.8K | 16,009 | −24% | −<0.01% (now 0.03%) | filing |
| 2026-06-30 | Hopper Jonathan Mark | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 5,000→ 5,000 Common Stock | — | — | 20,000 | — | — | filing |
| 2026-06-30 | Hopper Jonathan Mark | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 5,000→ 5,000 Common Stock | — | — | 25,000 | — | — | filing |
| 2026-06-30 | Hopper Jonathan Mark | Officer (Chief Medical Officer) | S | ▼ sell10b5-1 | 5,0000 | $45.00 | $225.0K | 75,753 | −6% | −<0.01% (now 0.15%) | filing |
| 2026-06-30 | Hopper Jonathan Mark | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 5,0000 | $29.82 | $149.1K | 80,753 | +7% | +<0.01% (now 0.16%) | filing |
| 2026-06-30 | Hopper Jonathan Mark | Officer (Chief Medical Officer) | S | ▼ sell10b5-1 | 5,0000 | $45.00 | $225.0K | 75,753 | −6% | −<0.01% (now 0.15%) | filing |
| 2026-06-30 | Hopper Jonathan Mark | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 5,0000 | $29.82 | $149.1K | 80,753 | +7% | +<0.01% (now 0.16%) | filing |
| 2026-06-30 | Flynn Sean C. | Officer (Chief Legal Officer) | M | ▲ buy10b5-1 | 15,000→ 15,000 Common Stock | — | — | 55,000 | — | — | filing |
| 2026-06-30 | Flynn Sean C. | Officer (Chief Legal Officer) | S | ▼ sell10b5-1 | 15,0000 | $45.64 | $684.6K | 1,647 | −90% | −0.03% (now <0.01%) | filing |
| 2026-06-30 | Flynn Sean C. | Officer (Chief Legal Officer) | M | ▲ buy10b5-1 | 15,0000 | $16.25 | $243.8K | 16,647 | 10× | +0.03% (now 0.03%) | filing |
| 2026-06-22 | Halpin Michael | Officer (Chief Operating Officer) | M | ▲ buy10b5-1 | 10,000→ 10,000 Common Stock | — | — | 36,250 | — | — | filing |
| 2026-06-22 | Halpin Michael | Officer (Chief Operating Officer) | S | ▼ sell10b5-1 | 10,0000 | $40.24 | $402.4K | 16,248 | −38% | −0.02% (now 0.03%) | filing |
| 2026-06-22 | Halpin Michael | Officer (Chief Operating Officer) | M | ▲ buy10b5-1 | 10,0000 | $16.66 | $166.6K | 26,248 | +62% | +0.02% (now 0.05%) | filing |
| 2026-06-22 | Flynn Sean C. | Officer (Chief Legal Officer) | M | ▲ buy10b5-1 | 15,000→ 15,000 Common Stock | — | — | 70,000 | — | — | filing |
| 2026-06-22 | Flynn Sean C. | Officer (Chief Legal Officer) | S | ▼ sell10b5-1 | 15,0000 | $40.21 | $603.1K | 1,647 | −90% | −0.03% (now <0.01%) | filing |
| 2026-06-22 | Flynn Sean C. | Officer (Chief Legal Officer) | M | ▲ buy10b5-1 | 15,0000 | $16.25 | $243.8K | 16,647 | 10× | +0.03% (now 0.03%) | filing |
| 2026-06-04 | Hopper Jonathan Mark | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 4,375→ 4,375 Common Stock | — | — | 1,625 | — | — | filing |
| 2026-06-04 | Hopper Jonathan Mark | Officer (Chief Medical Officer) | S | ▼ sell10b5-1 | 4,3750 | $35.00 | $153.1K | 75,753 | −5% | −<0.01% (now 0.15%) | filing |
| 2026-06-04 | Hopper Jonathan Mark | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 4,3750 | $16.66 | $72.9K | 80,128 | +6% | +<0.01% (now 0.16%) | filing |
| 2026-05-15 | MCLAUGHLIN KEVIN F | Director | M | ▲ buy10b5-1 | 3,500→ 3,500 Common Stock | — | — | 14,000 | — | — | filing |
| 2026-05-15 | MCLAUGHLIN KEVIN F | Director | M | ▲ buy10b5-1 | 3,500→ 3,500 Common Stock | — | — | 0 | — | — | filing |
| 2026-05-15 | MCLAUGHLIN KEVIN F | Director | S | ▼ sell10b5-1 | 3,5000 | $32.82 | $114.9K | 18,300 | −16% | −<0.01% (now 0.04%) | filing |
| 2026-05-15 | MCLAUGHLIN KEVIN F | Director | M | ▲ buy10b5-1 | 3,5000 | $13.05 | $45.7K | 21,800 | +19% | +<0.01% (now 0.04%) | filing |
| 2026-05-15 | MCLAUGHLIN KEVIN F | Director | S | ▼ sell10b5-1 | 3,5000 | $32.83 | $114.9K | 18,300 | −16% | −<0.01% (now 0.04%) | filing |
| 2026-05-15 | MCLAUGHLIN KEVIN F | Director | M | ▲ buy10b5-1 | 3,5000 | $2.63 | $9.2K | 21,800 | +19% | +<0.01% (now 0.04%) | filing |
| 2026-05-13 | Wotton Paul K | Director | S | ▼ sell | 7,5000 | $32.64 | $244.8K | 18,802 | −29% | −0.01% (now 0.04%) | filing |
| 2026-05-13 | Wotton Paul K | Director | S | ▼ sell | 2,5000 | $33.05 | $82.6K | 26,302 | −9% | −<0.01% (now 0.05%) | filing |
| 2026-05-08 | SIEGAL JONATHAN | Officer (Principal Accounting Officer) | S | ▼ sell10b5-1 | 1,4220 | $40.50 | $57.6K | 1,118 | −56% | −<0.01% (now <0.01%) | filing |
| 2026-05-08 | SIEGAL JONATHAN | Officer (Principal Accounting Officer) | S | ▼ sell10b5-1 | 3,4330 | $38.00 | $130.5K | 2,540 | −57% | −<0.01% (now <0.01%) | filing |
| 2026-05-08 | Mara Joseph Anthony Jr | Officer (Chief Financial Officer) | S | ▼ sell10b5-1 | 5,0000 | $40.50 | $202.5K | 21,009 | −19% | −<0.01% (now 0.04%) | filing |
| 2026-05-01 | Wotton Paul K | Director | A | ▲ buy | 3,200→ 3,200 Common Stock | — | — | 3,200 | — | — | filing |
| 2026-05-01 | Wotton Paul K | Director | A | ▲ buy | 8,000→ 8,000 Common Stock | — | — | 8,000 | — | — | filing |
| 2026-05-01 | Wotton Paul K | Director | M | ▲ buy | 3,200→ 3,200 Common Stock | — | — | 0 | — | — | filing |
| 2026-05-01 | Wotton Paul K | Director | M | ▲ buy | 3,2000 | — | — | 28,802 | +12% | +<0.01% (now 0.06%) | filing |
| 2026-05-01 | ZERBE ROBERT L MD | Director | A | ▲ buy | 3,200→ 3,200 Common Stock | — | — | 3,200 | — | — | filing |
| 2026-05-01 | ZERBE ROBERT L MD | Director | A | ▲ buy | 8,000→ 8,000 Common Stock | — | — | 8,000 | — | — | filing |
| 2026-05-01 | ZERBE ROBERT L MD | Director | M | ▲ buy | 3,200→ 3,200 Common Stock | — | — | 0 | — | — | filing |
| 2026-05-01 | ZERBE ROBERT L MD | Director | M | ▲ buy | 3,2000 | — | — | 32,995 | +11% | +<0.01% (now 0.06%) | filing |
| 2026-05-01 | WRIGHT LISA | Director | A | ▲ buy | 3,200→ 3,200 Common Stock | — | — | 3,200 | — | — | filing |
| 2026-05-01 | WRIGHT LISA | Director | A | ▲ buy | 8,000→ 8,000 Common Stock | — | — | 8,000 | — | — | filing |
| 2026-05-01 | WRIGHT LISA | Director | M | ▲ buy | 3,200→ 3,200 Common Stock | — | — | 0 | — | — | filing |
| 2026-05-01 | WRIGHT LISA | Director | M | ▲ buy | 3,2000 | — | — | 15,851 | +25% | +<0.01% (now 0.03%) | filing |
| 2026-05-01 | Rubino Alan L | Director | A | ▲ buy | 3,200→ 3,200 Common Stock | — | — | 3,200 | — | — | filing |
| 2026-05-01 | Rubino Alan L | Director | A | ▲ buy | 8,000→ 8,000 Common Stock | — | — | 8,000 | — | — | filing |
| 2026-05-01 | Rubino Alan L | Director | M | ▲ buy | 3,200→ 3,200 Common Stock | — | — | 0 | — | — | filing |
| 2026-05-01 | Rubino Alan L | Director | M | ▲ buy | 3,2000 | — | — | 64,194 | +5% | +<0.01% (now 0.13%) | filing |
| 2026-05-01 | MCLAUGHLIN KEVIN F | Director | A | ▲ buy | 3,200→ 3,200 Common Stock | — | — | 3,200 | — | — | filing |
| 2026-05-01 | MCLAUGHLIN KEVIN F | Director | A | ▲ buy | 8,000→ 8,000 Common Stock | — | — | 8,000 | — | — | filing |
| 2026-05-01 | MCLAUGHLIN KEVIN F | Director | M | ▲ buy | 3,200→ 3,200 Common Stock | — | — | 0 | — | — | filing |
| 2026-05-01 | MCLAUGHLIN KEVIN F | Director | M | ▲ buy | 3,2000 | — | — | 18,300 | +21% | +<0.01% (now 0.04%) | filing |
| 2026-05-01 | Hagen Heidi | Director | A | ▲ buy | 3,200→ 3,200 Common Stock | — | — | 3,200 | — | — | filing |
| 2026-05-01 | Hagen Heidi | Director | A | ▲ buy | 8,000→ 8,000 Common Stock | — | — | 8,000 | — | — | filing |
| 2026-05-01 | Hagen Heidi | Director | M | ▲ buy | 3,200→ 3,200 Common Stock | — | — | 0 | — | — | filing |
| 2026-05-01 | Hagen Heidi | Director | M | ▲ buy | 3,2000 | — | — | 35,050 | +10% | +<0.01% (now 0.07%) | filing |
| 2026-04-06 | Hopper Jonathan Mark | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 3,472→ 3,472 Common Stock | — | — | 9,132 | — | — | filing |
| 2026-04-06 | Hopper Jonathan Mark | Officer (Chief Medical Officer) | S | ▼ sell10b5-1 | 3,4720 | $35.00 | $121.5K | 75,556 | −4% | −<0.01% (now 0.15%) | filing |
| 2026-04-06 | Hopper Jonathan Mark | Officer (Chief Medical Officer) | M | ▲ buy10b5-1 | 3,4720 | $10.95 | $38.0K | 79,028 | +5% | +<0.01% (now 0.15%) | filing |
| 2026-03-27 | Rubino Alan L | Director | M | ▲ buy | 15,000→ 15,000 Common Stock | — | — | 0 | — | — | filing |
| 2026-03-27 | Rubino Alan L | Director | M | ▲ buy | 15,0000 | $2.76 | $41.4K | 60,994 | +33% | +0.03% (now 0.12%) | filing |
| 2026-03-25 | Hagen Heidi | Director | M | ▲ buy10b5-1 | 15,000→ 15,000 Common Stock | — | — | 0 | — | — | filing |
| 2026-03-25 | Hagen Heidi | Director | S | ▼ sell10b5-1 | 15,0000 | $32.41 | $486.1K | 31,850 | −32% | −0.03% (now 0.06%) | filing |
| 2026-03-25 | Hagen Heidi | Director | M | ▲ buy10b5-1 | 15,0000 | $2.76 | $41.4K | 46,850 | +47% | +0.03% (now 0.09%) | filing |
Up to 200 most recent filings · select a heading to sort, or open “How to read this” above for definitions · this company on SEC EDGAR.